晚期非小细胞肺癌个体化治疗的个案分析

Analysis of A Case of Advanced Non-small Cell Lung Cancer Treated with Individualized Therapy

晚期非小细胞肺癌患者预后不佳,总生存期为5～6个月,1年生存率为20%～25%,常规化疗延长2～3个月,对于这种情况目前出现了针对非小细胞肺癌治疗的新手段,如抗肿瘤新生血管治疗及靶向治疗;同时根据患者的体质状态、病理类型、肿瘤细胞的生物学特点进行个体化治疗,以达到更好的治疗效果及生存益处。现介绍1例经天津医科大学附属肿瘤医院肺部肿瘤内科治疗的非小细胞肺癌病例。该患者经常规化疗联合抗血管生成治疗后效果较佳,并通过CT灌注成像及检测循环血管内皮细胞水平进行多角度疗效评价,为建立完善的疗效评价体系建立基础。

The prognosis of patients with non-small cell lung cancer is poor and the overall survival is 5-6 months and the one-year survival rate is 20%-25%. Regular chemotherapy can prolong patient survival for 2-3 months. Currently, new treatments such as antiangiogenic and target therapy have appeared. At the same time individualized therapy according to the performance of patients, pathological type and biological characteristics of tumor cell is considered in order to reach good therapeutic effect and survival. We will introduce one patient with non-small cell lung cancer treated with individualized therapy in our department. Chemotherapy and anti-vascular therapy achieved good results in this patient. CT perfusion and cECs were applied to evaluate the effect of the therapy.